share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Greene John

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Greene John

CRISPR Therapeutics | 4：持股变动声明-董事 Greene John
美股sec公告 ·  05/31 16:21
Moomoo AI 已提取核心信息
In a recent transaction, John Greene, associated with CRISPR Therapeutics (CRSP.US), executed a stock action on 05/30/2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and post-action shareholding, were not disclosed in the announcement. Investors are advised to monitor CRISPR Therapeutics for any further disclosures that may provide additional insights into the transaction's impact on the company's stock.
In a recent transaction, John Greene, associated with CRISPR Therapeutics (CRSP.US), executed a stock action on 05/30/2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and post-action shareholding, were not disclosed in the announcement. Investors are advised to monitor CRISPR Therapeutics for any further disclosures that may provide additional insights into the transaction's impact on the company's stock.
在最近的一笔交易中，与CRISPR Therapeutics（CRSP.US）相关的约翰·格林于2024年5月30日执行了股票行动。公告中未披露该交易的具体细节，包括行动类型、状态、所涉股份数量、股票性质、交易价格和事后持股。建议投资者关注CRISPR Therapeutics是否有任何进一步的披露，这些披露可能为该交易对公司股票的影响提供更多见解。
在最近的一笔交易中，与CRISPR Therapeutics（CRSP.US）相关的约翰·格林于2024年5月30日执行了股票行动。公告中未披露该交易的具体细节，包括行动类型、状态、所涉股份数量、股票性质、交易价格和事后持股。建议投资者关注CRISPR Therapeutics是否有任何进一步的披露，这些披露可能为该交易对公司股票的影响提供更多见解。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息